A detailed history of Marshall Wace, LLP transactions in Morpho Sys Ag stock. As of the latest transaction made, Marshall Wace, LLP holds 264,961 shares of MOR stock, worth $4.82 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
264,961
Previous 326,086 18.75%
Holding current value
$4.82 Million
Previous $3.23 Million 48.88%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$8.6 - $18.18 $525,675 - $1.11 Million
-61,125 Reduced 18.75%
264,961 $4.81 Million
Q4 2023

Feb 14, 2024

BUY
$4.55 - $9.9 $743,529 - $1.62 Million
163,413 Added 100.45%
326,086 $3.23 Million
Q3 2023

Nov 14, 2023

SELL
$6.72 - $8.6 $227,814 - $291,548
-33,901 Reduced 17.25%
162,673 $1.09 Million
Q2 2023

Aug 14, 2023

BUY
$3.95 - $7.74 $776,467 - $1.52 Million
196,574 New
196,574 $1.47 Million
Q1 2022

May 16, 2022

SELL
$5.87 - $9.73 $66,319 - $109,929
-11,298 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$9.08 - $12.45 $192,450 - $263,877
-21,195 Reduced 65.23%
11,298 $107,000
Q3 2021

Nov 15, 2021

BUY
$11.76 - $19.51 $260,495 - $432,166
22,151 Added 214.18%
32,493 $382,000
Q2 2021

Aug 13, 2021

BUY
$18.95 - $23.95 $195,980 - $247,690
10,342 New
10,342 $199,000
Q1 2021

May 17, 2021

SELL
$21.56 - $30.66 $396,337 - $563,622
-18,383 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$24.81 - $30.33 $1.09 Million - $1.33 Million
-43,764 Reduced 70.42%
18,383 $521,000
Q3 2020

Nov 16, 2020

SELL
$30.28 - $35.72 $100,650 - $118,733
-3,324 Reduced 5.08%
62,147 $1.95 Million
Q2 2020

Aug 13, 2020

BUY
$24.08 - $33.35 $1.58 Million - $2.18 Million
65,471 New
65,471 $2.07 Million
Q2 2019

Aug 14, 2019

SELL
$23.24 - $26.76 $91,565 - $105,434
-3,940 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$22.55 - $29.84 $542,688 - $718,129
-24,066 Reduced 85.93%
3,940 $90,000
Q4 2018

Feb 14, 2019

BUY
$21.96 - $31.02 $615,011 - $868,746
28,006 New
28,006 $707,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Market Cap $2.49B
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.